1. Home
  2. PLAB vs BCYC Comparison

PLAB vs BCYC Comparison

Compare PLAB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Photronics Inc.

PLAB

Photronics Inc.

HOLD

Current Price

$36.73

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$7.29

Market Cap

516.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLAB
BCYC
Founded
1969
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
516.8M
IPO Year
1987
2019

Fundamental Metrics

Financial Performance
Metric
PLAB
BCYC
Price
$36.73
$7.29
Analyst Decision
Strong Buy
Buy
Analyst Count
2
11
Target Price
$43.50
$18.73
AVG Volume (30 Days)
1.8M
293.3K
Earning Date
12-10-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
9.09
N/A
EPS
2.28
N/A
Revenue
$849,294,000.00
$28,339,000.00
Revenue This Year
$4.63
N/A
Revenue Next Year
$6.20
N/A
P/E Ratio
$15.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.46
$6.03
52 Week High
$39.80
$21.14

Technical Indicators

Market Signals
Indicator
PLAB
BCYC
Relative Strength Index (RSI) 78.97 52.53
Support Level $35.69 $7.03
Resistance Level $39.80 $7.65
Average True Range (ATR) 1.61 0.37
MACD 1.71 0.08
Stochastic Oscillator 83.24 53.12

Price Performance

Historical Comparison
PLAB
BCYC

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz or glass plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue world-wide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: